In addition, Tekmira Pharmaceuticals has developed TKM-PLK1 that targets polo-like kinase 1 (PLK1) for solid tumors and TKM-Ebola to treat Ebola virus infection. The gene discussed is PLK1; the disease is Ebola hemorrhagic fever.